Full Press Release Details
Receives Additional Grant Funding
Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development
ZIONA, ISRAEL, August 14, 2017 -
Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the Israel Innovation Authority (IIA), formerly known
as the Office of the Chief Scientist, agreed to fund up to 40% of a NIS 2.7 million (approximately US$ 750,000) budget towards
ongoing development of M-001, the Company's Universal Flu Vaccine candidate.
six previously completed human clinical trials, including the recently completed Phase 2b trial held in Europe[1],
BiondVax's M-001 was shown to be safe and immunogenic towards multiple flu strains. Including today's grant approval,
since 2006 the IIA has granted over US$ 6 million in funding to BiondVax. The non-dilutive grants will become repayable from royalties
generated from future sales of BiondVax's vaccine, once commercially available on the market.
Tammy Ben-Yedidia, Chief Scientific Officer of BiondVax commented, "The ongoing support of our program by the IIA is
proof of their long-term confidence in BiondVax's innovative flu vaccine. This grant, together with other generous recently approved
financing to the company[2],[3] brings us closer to launching a Phase 3 clinical trial."
BiondVax Pharmaceuticals Ltd
is a clinical phase biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season
protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes
a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system
for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. Please visit www.biondvax.com.
further information, please contact:
BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine. http://www.biondvax.com/2017/07/biondvax-reports-positive-phase-2b-clinical-trial-results-for-its-universal-flu-vaccine/
European Investment Bank (EIB) supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine
BiondVax Approved for Grant from Israel's Ministry of Economy and Industry to Build Facility for Commercial Scale
Forward Looking Statements
press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such
as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These
forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to
certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results
to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but
are not limited to, uncertainties and risks in the clinical development process, including, among others, length, expense and
the ability to enroll trial patients, timing of receipt of funding from grants, reliance on third parties and that the results
of earlier research and/or preclinical or clinical trial results may not be predictive of actual results, conclusions or interpretations
of subsequent research or trials, the results of the Phase 2 & 3 trials, delays or obstacles
in launching and/or successfully completing our clinical trials, the lengthy and unpredictable nature of the FDA and other
regulatory authorities approval processes, our ability to satisfy rigorous regulatory requirements,
the impact of the global economic environment on the Company customer target base, the adequacy of available cash resource
and the ability to raise capital when needed. More detailed information about the risks
and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form
20-F for the year ended December 31, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on
the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange.
Einstein Street, P.O. Box 4143, Kiryat Weizmann, Ness-Ziona, 7414002, ISRAEL
+972-8-9302529 Fax: +972-8-9302531 www.BiondVax.com